Fundamental Analysis of KALA BIO INC(NASDAQ:KALA) stock

Fundamental Rating

Taking everything into account, KALA scores 1 out of 10 in our fundamental rating. KALA was compared to 588 industry peers in the Biotechnology industry. Both the profitability and financial health of KALA have multiple concerns. KALA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

KALA had negative earnings in the past year.

KALA had a negative operating cash flow in the past year.

In the past 5 years KALA always reported negative net income.

KALA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

KALA has a Return On Assets of -75.42%. This is in the lower half of the industry: KALA underperforms 68.43% of its industry peers.

Looking at the Return On Equity, with a value of -562.33%, KALA is doing worse than 80.89% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-75.42%
ROE	-562.33%
ROIC	N/A

ROA(3y)-76.45%

ROA(5y)-67.52%

ROE(3y)-549.04%

ROE(5y)-413.82%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KALA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

KALA does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, KALA has more shares outstanding

The number of shares outstanding for KALA has been increased compared to 5 years ago.

The debt/assets ratio for KALA is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -16.90, we must say that KALA is in the distress zone and has some risk of bankruptcy.

KALA has a Altman-Z score of -16.90. This is amonst the worse of the industry: KALA underperforms 85.32% of its industry peers.

KALA has a Debt/Equity ratio of 4.56. This is a high value indicating a heavy dependency on external financing.

KALA's Debt to Equity ratio of 4.56 is on the low side compared to the rest of the industry. KALA is outperformed by 83.62% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	4.56
Debt/FCF	N/A
Altman-Z	-16.9

ROIC/WACCN/A

WACC8.1%

2.3 Liquidity

KALA has a Current Ratio of 6.33. This indicates that KALA is financially healthy and has no problem in meeting its short term obligations.

KALA's Current ratio of 6.33 is fine compared to the rest of the industry. KALA outperforms 64.51% of its industry peers.

A Quick Ratio of 6.33 indicates that KALA has no problem at all paying its short term obligations.

The Quick ratio of KALA (6.33) is better than 64.85% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.33
Quick Ratio	6.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

KALA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.64%, which is quite impressive.

Looking at the last year, KALA shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)40.64%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q60.1%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

The Earnings Per Share is expected to grow by 16.03% on average over the next years. This is quite good.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y42.18%

EPS Next 2Y16.03%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

KALA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year KALA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as KALA's earnings are expected to grow with 16.03% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y16.03%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KALA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KALA BIO INC

NASDAQ:KALA (5/2/2024, 7:03:06 PM)

6.7549

-0.06 (-0.81%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap19.05M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-75.42%
ROE	-562.33%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	4.56
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.33
Quick Ratio	6.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)40.64%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y42.18%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

KALA BIO INC (KALA)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens